 Stefan Sillau
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 20 | 2024 | 323 | 2.380 |
Why?
| | Palliative Care | 12 | 2024 | 639 | 0.940 |
Why?
| | Multiple Sclerosis | 7 | 2023 | 380 | 0.890 |
Why?
| | Caregivers | 9 | 2024 | 712 | 0.750 |
Why?
| | Seizures | 8 | 2023 | 341 | 0.690 |
Why?
| | Quality of Life | 15 | 2024 | 2359 | 0.680 |
Why?
| | Alzheimer Disease | 5 | 2024 | 436 | 0.630 |
Why?
| | Epilepsy | 4 | 2023 | 278 | 0.570 |
Why?
| | Drug Resistant Epilepsy | 3 | 2023 | 45 | 0.560 |
Why?
| | Natalizumab | 4 | 2021 | 46 | 0.530 |
Why?
| | Parkinsonian Disorders | 3 | 2020 | 27 | 0.500 |
Why?
| | Fingolimod Hydrochloride | 3 | 2020 | 30 | 0.490 |
Why?
| | Humans | 93 | 2024 | 115042 | 0.430 |
Why?
| | Immunologic Factors | 3 | 2020 | 221 | 0.420 |
Why?
| | Atherosclerosis | 4 | 2019 | 342 | 0.410 |
Why?
| | Ambulatory Care | 3 | 2020 | 478 | 0.390 |
Why?
| | Diabetic Neuropathies | 2 | 2023 | 79 | 0.380 |
Why?
| | Charcot-Marie-Tooth Disease | 2 | 2022 | 19 | 0.380 |
Why?
| | Sinusitis | 3 | 2021 | 175 | 0.370 |
Why?
| | Chagas Disease | 2 | 2021 | 34 | 0.360 |
Why?
| | Music Therapy | 2 | 2021 | 21 | 0.360 |
Why?
| | Male | 53 | 2024 | 55731 | 0.340 |
Why?
| | Middle Aged | 37 | 2021 | 26827 | 0.340 |
Why?
| | Aged | 31 | 2024 | 19119 | 0.340 |
Why?
| | Retrospective Studies | 27 | 2024 | 12547 | 0.340 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 0.330 |
Why?
| | Torticollis | 2 | 2019 | 12 | 0.330 |
Why?
| | Female | 53 | 2023 | 59613 | 0.320 |
Why?
| | Rituximab | 2 | 2020 | 150 | 0.320 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 69 | 0.320 |
Why?
| | Meningitis, Cryptococcal | 2 | 2019 | 28 | 0.320 |
Why?
| | Dystonic Disorders | 2 | 2019 | 16 | 0.310 |
Why?
| | Cardiomyopathies | 2 | 2021 | 300 | 0.290 |
Why?
| | Adult | 31 | 2023 | 30656 | 0.290 |
Why?
| | Spirituality | 4 | 2021 | 69 | 0.290 |
Why?
| | Medical Staff, Hospital | 2 | 2021 | 74 | 0.280 |
Why?
| | Myelitis | 2 | 2018 | 88 | 0.280 |
Why?
| | Sepsis | 2 | 2022 | 508 | 0.270 |
Why?
| | Neurosurgical Procedures | 2 | 2017 | 154 | 0.260 |
Why?
| | Cognition | 5 | 2023 | 983 | 0.250 |
Why?
| | Adaptation, Psychological | 5 | 2020 | 547 | 0.250 |
Why?
| | Magnetic Resonance Imaging | 10 | 2024 | 3118 | 0.240 |
Why?
| | Child Abuse | 2 | 2022 | 451 | 0.240 |
Why?
| | Aged, 80 and over | 14 | 2021 | 6357 | 0.240 |
Why?
| | Telemedicine | 2 | 2024 | 665 | 0.240 |
Why?
| | Nasal Polyps | 2 | 2016 | 49 | 0.230 |
Why?
| | Patient Care Team | 3 | 2019 | 515 | 0.230 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 9 | 0.230 |
Why?
| | Cognition Disorders | 2 | 2018 | 475 | 0.230 |
Why?
| | Cost of Illness | 3 | 2021 | 254 | 0.230 |
Why?
| | Inpatients | 3 | 2021 | 378 | 0.230 |
Why?
| | Dimethyl Fumarate | 2 | 2020 | 10 | 0.220 |
Why?
| | Severity of Illness Index | 8 | 2020 | 2551 | 0.210 |
Why?
| | Frontotemporal Dementia | 1 | 2022 | 20 | 0.200 |
Why?
| | Sleep | 3 | 2021 | 631 | 0.200 |
Why?
| | Apolipoprotein E4 | 1 | 2022 | 32 | 0.200 |
Why?
| | Cannabidiol | 1 | 2023 | 60 | 0.200 |
Why?
| | Vagus Nerve Stimulation | 1 | 2022 | 21 | 0.200 |
Why?
| | Conversion Disorder | 1 | 2022 | 9 | 0.200 |
Why?
| | Epilepsies, Partial | 1 | 2022 | 29 | 0.200 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 4411 | 0.190 |
Why?
| | Memory Consolidation | 1 | 2021 | 11 | 0.190 |
Why?
| | Risk Assessment | 6 | 2023 | 2976 | 0.190 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 22 | 0.190 |
Why?
| | Motor Disorders | 1 | 2021 | 16 | 0.190 |
Why?
| | Disease Progression | 4 | 2022 | 2389 | 0.190 |
Why?
| | Dermatitis, Seborrheic | 1 | 2020 | 4 | 0.190 |
Why?
| | Colorado | 11 | 2021 | 4089 | 0.180 |
Why?
| | Intellectual Disability | 1 | 2022 | 129 | 0.180 |
Why?
| | Attitude of Health Personnel | 2 | 2021 | 976 | 0.180 |
Why?
| | Treatment Outcome | 12 | 2022 | 9122 | 0.180 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2022 | 69 | 0.180 |
Why?
| | Vitamin D | 2 | 2015 | 340 | 0.180 |
Why?
| | Young Adult | 14 | 2022 | 10498 | 0.180 |
Why?
| | Self Report | 3 | 2022 | 698 | 0.180 |
Why?
| | Basal Ganglia Diseases | 1 | 2020 | 8 | 0.180 |
Why?
| | Cytokines | 3 | 2022 | 1843 | 0.180 |
Why?
| | Electronic Health Records | 2 | 2021 | 799 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1138 | 0.180 |
Why?
| | Terminal Care | 1 | 2023 | 213 | 0.180 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 25 | 0.180 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.170 |
Why?
| | Interferon-gamma | 1 | 2023 | 723 | 0.170 |
Why?
| | Neurovascular Coupling | 1 | 2019 | 7 | 0.170 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2098 | 0.170 |
Why?
| | Disabled Persons | 1 | 2021 | 133 | 0.170 |
Why?
| | Shock, Septic | 1 | 2021 | 186 | 0.170 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 273 | 0.160 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 182 | 0.160 |
Why?
| | Cohort Studies | 8 | 2021 | 4904 | 0.160 |
Why?
| | Streptococcal Infections | 1 | 2021 | 127 | 0.160 |
Why?
| | Behavioral Symptoms | 1 | 2019 | 40 | 0.160 |
Why?
| | Down Syndrome | 2 | 2022 | 335 | 0.160 |
Why?
| | Cannabinoids | 1 | 2020 | 115 | 0.160 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 20 | 0.160 |
Why?
| | Electroencephalography | 4 | 2022 | 362 | 0.160 |
Why?
| | Critical Care Outcomes | 1 | 2018 | 12 | 0.160 |
Why?
| | Psychotherapy, Group | 1 | 2019 | 61 | 0.160 |
Why?
| | Psychometrics | 2 | 2019 | 608 | 0.160 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 33 | 0.160 |
Why?
| | Restless Legs Syndrome | 1 | 2018 | 18 | 0.160 |
Why?
| | Blepharospasm | 1 | 2018 | 7 | 0.160 |
Why?
| | Fluoxetine | 1 | 2018 | 46 | 0.160 |
Why?
| | Proxy | 1 | 2018 | 23 | 0.150 |
Why?
| | Brain | 5 | 2022 | 2380 | 0.150 |
Why?
| | Aftercare | 1 | 2020 | 186 | 0.150 |
Why?
| | Basal Ganglia | 1 | 2018 | 42 | 0.150 |
Why?
| | Subthalamic Nucleus | 1 | 2018 | 38 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 87 | 0.150 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 651 | 0.150 |
Why?
| | Neurology | 1 | 2019 | 84 | 0.150 |
Why?
| | Nutrition Surveys | 1 | 2019 | 224 | 0.150 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2018 | 63 | 0.150 |
Why?
| | Autism Spectrum Disorder | 1 | 2022 | 322 | 0.150 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 211 | 0.150 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2017 | 26 | 0.150 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2017 | 43 | 0.150 |
Why?
| | Prevalence | 6 | 2022 | 2255 | 0.140 |
Why?
| | Follow-Up Studies | 7 | 2020 | 4420 | 0.140 |
Why?
| | Deep Brain Stimulation | 1 | 2018 | 71 | 0.140 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 89 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2019 | 251 | 0.140 |
Why?
| | Cranial Nerve Diseases | 1 | 2017 | 42 | 0.140 |
Why?
| | Immunoglobulin G | 1 | 2021 | 776 | 0.140 |
Why?
| | Movement Disorders | 1 | 2017 | 46 | 0.140 |
Why?
| | Adolescent | 13 | 2023 | 17864 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2018 | 97 | 0.140 |
Why?
| | Dementia | 1 | 2019 | 186 | 0.140 |
Why?
| | Cannabis | 1 | 2023 | 384 | 0.140 |
Why?
| | Orbital Diseases | 1 | 2016 | 25 | 0.140 |
Why?
| | Muscular Diseases | 1 | 2017 | 106 | 0.140 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 6 | 0.140 |
Why?
| | Child | 13 | 2022 | 18407 | 0.140 |
Why?
| | Atrophy | 3 | 2024 | 151 | 0.140 |
Why?
| | Cerebellum | 1 | 2018 | 200 | 0.130 |
Why?
| | Craniocerebral Trauma | 1 | 2017 | 128 | 0.130 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 25 | 0.130 |
Why?
| | Models, Theoretical | 1 | 2020 | 517 | 0.130 |
Why?
| | Meningioma | 1 | 2016 | 78 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 123 | 0.130 |
Why?
| | Longitudinal Studies | 3 | 2022 | 2389 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1747 | 0.130 |
Why?
| | Risk Factors | 9 | 2019 | 8642 | 0.130 |
Why?
| | Meningeal Neoplasms | 1 | 2016 | 88 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2021 | 321 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2018 | 224 | 0.120 |
Why?
| | Regression Analysis | 2 | 2018 | 948 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 374 | 0.120 |
Why?
| | Hemodynamics | 1 | 2019 | 1017 | 0.120 |
Why?
| | Motor Activity | 1 | 2019 | 642 | 0.120 |
Why?
| | Stroke | 2 | 2020 | 1015 | 0.120 |
Why?
| | Data Collection | 2 | 2022 | 623 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 772 | 0.120 |
Why?
| | Craniofacial Abnormalities | 1 | 2015 | 59 | 0.120 |
Why?
| | Patient Readmission | 1 | 2020 | 606 | 0.120 |
Why?
| | Aspirin | 2 | 2016 | 324 | 0.120 |
Why?
| | Rhinitis | 1 | 2016 | 128 | 0.120 |
Why?
| | Retinopathy of Prematurity | 1 | 2016 | 111 | 0.120 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 913 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 856 | 0.120 |
Why?
| | Neonatal Screening | 1 | 2016 | 152 | 0.120 |
Why?
| | Anxiety Disorders | 1 | 2017 | 307 | 0.120 |
Why?
| | Vitamin D Deficiency | 2 | 2015 | 158 | 0.120 |
Why?
| | Urolithiasis | 1 | 2014 | 8 | 0.110 |
Why?
| | Ureteroscopy | 1 | 2014 | 16 | 0.110 |
Why?
| | Depressive Disorder | 1 | 2017 | 333 | 0.110 |
Why?
| | Eosinophilia | 1 | 2016 | 186 | 0.110 |
Why?
| | Chronic Disease | 2 | 2016 | 1591 | 0.110 |
Why?
| | Behavioral Medicine | 1 | 2014 | 37 | 0.110 |
Why?
| | Patient-Centered Care | 1 | 2019 | 474 | 0.110 |
Why?
| | Mental Disorders | 1 | 2021 | 897 | 0.110 |
Why?
| | Nervous System Diseases | 1 | 2016 | 252 | 0.110 |
Why?
| | Extremities | 1 | 2014 | 113 | 0.110 |
Why?
| | Tonsillectomy | 1 | 2015 | 72 | 0.110 |
Why?
| | Prognosis | 4 | 2023 | 3334 | 0.110 |
Why?
| | Rural Health Services | 1 | 2014 | 92 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2341 | 0.110 |
Why?
| | Primary Prevention | 1 | 2015 | 171 | 0.110 |
Why?
| | Refugees | 1 | 2014 | 54 | 0.110 |
Why?
| | Pulmonary Ventilation | 1 | 2013 | 72 | 0.110 |
Why?
| | Demography | 1 | 2014 | 261 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2018 | 647 | 0.110 |
Why?
| | Incidence | 4 | 2022 | 2318 | 0.110 |
Why?
| | Birth Weight | 1 | 2016 | 440 | 0.110 |
Why?
| | Airway Obstruction | 1 | 2015 | 168 | 0.110 |
Why?
| | Curriculum | 1 | 2019 | 843 | 0.100 |
Why?
| | Weight Gain | 1 | 2016 | 451 | 0.100 |
Why?
| | Movement | 1 | 2014 | 246 | 0.100 |
Why?
| | Coronary Vessels | 1 | 2014 | 230 | 0.100 |
Why?
| | Teaching Rounds | 1 | 2013 | 64 | 0.100 |
Why?
| | Depression | 1 | 2020 | 1136 | 0.100 |
Why?
| | Coronary Disease | 1 | 2014 | 347 | 0.100 |
Why?
| | Calcinosis | 1 | 2014 | 242 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 194 | 0.100 |
Why?
| | Tissue Donors | 1 | 2014 | 326 | 0.100 |
Why?
| | Environmental Monitoring | 1 | 2013 | 254 | 0.100 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 231 | 0.090 |
Why?
| | Reproducibility of Results | 4 | 2022 | 2799 | 0.090 |
Why?
| | Internal Medicine | 1 | 2013 | 211 | 0.090 |
Why?
| | Surveys and Questionnaires | 6 | 2019 | 4631 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2014 | 339 | 0.090 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 372 | 0.090 |
Why?
| | Obesity | 2 | 2021 | 2524 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 189 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2014 | 237 | 0.090 |
Why?
| | United States | 7 | 2022 | 12226 | 0.090 |
Why?
| | Family | 1 | 2014 | 591 | 0.090 |
Why?
| | Polysomnography | 3 | 2015 | 135 | 0.090 |
Why?
| | Time Factors | 5 | 2020 | 6141 | 0.090 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 122 | 0.090 |
Why?
| | Cross Infection | 1 | 2012 | 199 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2023 | 3015 | 0.090 |
Why?
| | Postoperative Complications | 2 | 2017 | 2150 | 0.090 |
Why?
| | Models, Statistical | 1 | 2013 | 602 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2017 | 984 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 941 | 0.080 |
Why?
| | Phenotype | 1 | 2017 | 2815 | 0.080 |
Why?
| | Cardiac Surgical Procedures | 1 | 2013 | 413 | 0.080 |
Why?
| | Health Status | 1 | 2014 | 722 | 0.080 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 608 | 0.080 |
Why?
| | Quality of Health Care | 1 | 2013 | 573 | 0.080 |
Why?
| | Calcium | 1 | 2014 | 1104 | 0.080 |
Why?
| | Blood Pressure | 1 | 2014 | 1539 | 0.080 |
Why?
| | Prospective Studies | 5 | 2023 | 6232 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1477 | 0.080 |
Why?
| | Intensive Care Units | 1 | 2012 | 618 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2014 | 765 | 0.070 |
Why?
| | Length of Stay | 1 | 2012 | 950 | 0.070 |
Why?
| | Patient Participation | 2 | 2022 | 360 | 0.070 |
Why?
| | Internet | 1 | 2011 | 600 | 0.070 |
Why?
| | Heart Defects, Congenital | 1 | 2013 | 665 | 0.070 |
Why?
| | Critical Illness | 1 | 2012 | 644 | 0.070 |
Why?
| | Lung Diseases | 1 | 2013 | 703 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2023 | 1664 | 0.070 |
Why?
| | Asthma | 3 | 2016 | 2051 | 0.070 |
Why?
| | Recurrence | 2 | 2020 | 941 | 0.070 |
Why?
| | Hypertension | 1 | 2014 | 1058 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2019 | 746 | 0.070 |
Why?
| | Influenza, Human | 1 | 2011 | 546 | 0.070 |
Why?
| | Survival Analysis | 2 | 2019 | 1211 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1184 | 0.060 |
Why?
| | Child, Preschool | 4 | 2020 | 9093 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1214 | 0.060 |
Why?
| | Research Design | 2 | 2021 | 930 | 0.060 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 232 | 0.060 |
Why?
| | Anxiety | 2 | 2021 | 845 | 0.060 |
Why?
| | Primary Health Care | 1 | 2014 | 1512 | 0.060 |
Why?
| | Comorbidity | 2 | 2021 | 1457 | 0.060 |
Why?
| | Pandemics | 2 | 2022 | 1321 | 0.060 |
Why?
| | Neurologists | 1 | 2024 | 18 | 0.060 |
Why?
| | Amyloidogenic Proteins | 1 | 2023 | 9 | 0.060 |
Why?
| | Vaccination | 1 | 2011 | 1205 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2020 | 1715 | 0.060 |
Why?
| | Intermediate Filaments | 1 | 2023 | 46 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2023 | 34 | 0.050 |
Why?
| | Biomarkers | 2 | 2023 | 3419 | 0.050 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 96 | 0.050 |
Why?
| | tau Proteins | 1 | 2023 | 65 | 0.050 |
Why?
| | Myelin P0 Protein | 1 | 2022 | 7 | 0.050 |
Why?
| | Imipramine | 1 | 2022 | 12 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1736 | 0.050 |
Why?
| | Pain | 2 | 2018 | 709 | 0.050 |
Why?
| | Facial Expression | 1 | 2022 | 60 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 372 | 0.050 |
Why?
| | Dronabinol | 1 | 2023 | 118 | 0.050 |
Why?
| | Inflammation | 2 | 2022 | 2485 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2022 | 197 | 0.050 |
Why?
| | Polymerization | 1 | 2022 | 119 | 0.050 |
Why?
| | Vagus Nerve | 1 | 2022 | 81 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1812 | 0.050 |
Why?
| | Reference Standards | 1 | 2022 | 159 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 140 | 0.050 |
Why?
| | Catalysis | 1 | 2022 | 292 | 0.050 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.050 |
Why?
| | Oncology Service, Hospital | 1 | 2021 | 14 | 0.050 |
Why?
| | Interneurons | 1 | 2022 | 96 | 0.050 |
Why?
| | Lung | 1 | 2013 | 3595 | 0.050 |
Why?
| | Outpatients | 1 | 2024 | 328 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 161 | 0.050 |
Why?
| | Immune System | 1 | 2022 | 172 | 0.050 |
Why?
| | Hospitals, University | 1 | 2021 | 170 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 137 | 0.040 |
Why?
| | Astrocytes | 1 | 2022 | 162 | 0.040 |
Why?
| | Reaction Time | 1 | 2022 | 375 | 0.040 |
Why?
| | Serine | 1 | 2021 | 126 | 0.040 |
Why?
| | Infant | 3 | 2018 | 7946 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 522 | 0.040 |
Why?
| | Medical Informatics | 1 | 2021 | 91 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2021 | 124 | 0.040 |
Why?
| | Electrodes, Implanted | 1 | 2020 | 91 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 249 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 340 | 0.040 |
Why?
| | Multiple System Atrophy | 1 | 2019 | 4 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 335 | 0.040 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2019 | 5 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2022 | 238 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2023 | 668 | 0.040 |
Why?
| | Income | 1 | 2020 | 167 | 0.040 |
Why?
| | Lewy Body Disease | 1 | 2019 | 16 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
| | Qualitative Research | 1 | 2024 | 935 | 0.040 |
Why?
| | Music | 1 | 2019 | 39 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 48 | 0.040 |
Why?
| | Stroke Volume | 1 | 2021 | 510 | 0.040 |
Why?
| | Logistic Models | 2 | 2014 | 1839 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 56 | 0.040 |
Why?
| | Gait | 1 | 2021 | 249 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 118 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 665 | 0.040 |
Why?
| | Carnitine | 1 | 2018 | 62 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 730 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 413 | 0.040 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 469 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 772 | 0.040 |
Why?
| | Phosphorus | 1 | 2018 | 81 | 0.040 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 75 | 0.040 |
Why?
| | Age of Onset | 1 | 2019 | 449 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 278 | 0.040 |
Why?
| | Muscle Spasticity | 1 | 2018 | 53 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 130 | 0.040 |
Why?
| | Health Services | 1 | 2019 | 103 | 0.040 |
Why?
| | Neural Pathways | 1 | 2019 | 259 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 66 | 0.040 |
Why?
| | Emotions | 1 | 2022 | 473 | 0.040 |
Why?
| | Gadolinium | 1 | 2018 | 78 | 0.040 |
Why?
| | Hippocampus | 1 | 2022 | 697 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2022 | 635 | 0.040 |
Why?
| | Neural Conduction | 1 | 2017 | 79 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 447 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2019 | 271 | 0.040 |
Why?
| | Exophthalmos | 1 | 2016 | 19 | 0.030 |
Why?
| | Neuroimaging | 1 | 2019 | 251 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 1721 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 9 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 13 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2019 | 584 | 0.030 |
Why?
| | Brain Ischemia | 1 | 2020 | 297 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 7 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 124 | 0.030 |
Why?
| | Self Efficacy | 1 | 2019 | 355 | 0.030 |
Why?
| | Brain Mapping | 1 | 2019 | 523 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 719 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2016 | 243 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 44 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2018 | 351 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2016 | 104 | 0.030 |
Why?
| | Electromyography | 1 | 2017 | 326 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 178 | 0.030 |
Why?
| | Sleep Stages | 1 | 2015 | 61 | 0.030 |
Why?
| | Contrast Media | 1 | 2018 | 369 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 250 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 74 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2017 | 484 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2016 | 5040 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1375 | 0.030 |
Why?
| | Age Factors | 1 | 2022 | 2894 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 85 | 0.030 |
Why?
| | Thinness | 1 | 2015 | 87 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2015 | 60 | 0.030 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 74 | 0.030 |
Why?
| | San Francisco | 1 | 2014 | 56 | 0.030 |
Why?
| | Sampling Studies | 1 | 2014 | 94 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1127 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 109 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1046 | 0.030 |
Why?
| | Sternotomy | 1 | 2013 | 18 | 0.030 |
Why?
| | Critical Care | 1 | 2017 | 475 | 0.030 |
Why?
| | Lithotripsy | 1 | 2014 | 40 | 0.030 |
Why?
| | Physician-Nurse Relations | 1 | 2013 | 15 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 957 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 117 | 0.030 |
Why?
| | Leukotriene E4 | 1 | 2013 | 27 | 0.030 |
Why?
| | Thoracotomy | 1 | 2013 | 67 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 679 | 0.030 |
Why?
| | Spirometry | 1 | 2013 | 225 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2013 | 137 | 0.030 |
Why?
| | Gestational Age | 1 | 2016 | 758 | 0.030 |
Why?
| | Linear Models | 1 | 2015 | 776 | 0.030 |
Why?
| | Paranasal Sinuses | 1 | 2013 | 66 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2013 | 103 | 0.030 |
Why?
| | Drug Resistance | 1 | 2013 | 158 | 0.030 |
Why?
| | Olfaction Disorders | 1 | 2013 | 50 | 0.030 |
Why?
| | Vital Capacity | 1 | 2013 | 257 | 0.030 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 244 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2022 | 3545 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2014 | 617 | 0.030 |
Why?
| | Mutation | 1 | 2022 | 3350 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2013 | 476 | 0.020 |
Why?
| | Paper | 1 | 2011 | 8 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2014 | 307 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 538 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 185 | 0.020 |
Why?
| | Personnel, Hospital | 1 | 2011 | 24 | 0.020 |
Why?
| | Aging | 1 | 2021 | 1624 | 0.020 |
Why?
| | Premature Birth | 1 | 2015 | 277 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 306 | 0.020 |
Why?
| | Urban Population | 1 | 2014 | 401 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 281 | 0.020 |
Why?
| | Exercise Test | 1 | 2013 | 545 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2013 | 588 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2013 | 217 | 0.020 |
Why?
| | Patient Admission | 1 | 2012 | 175 | 0.020 |
Why?
| | Cause of Death | 1 | 2012 | 364 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1081 | 0.020 |
Why?
| | Recovery of Function | 1 | 2013 | 575 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 880 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1080 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1636 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1488 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2014 | 480 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1398 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2011 | 496 | 0.020 |
Why?
| | Patient Discharge | 1 | 2012 | 767 | 0.020 |
Why?
| | Mice | 1 | 2022 | 14927 | 0.020 |
Why?
| | Animals | 1 | 2022 | 31867 | 0.010 |
Why?
|
|
Sillau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|